Zahlen für Q1/23

• keine Umsätze
  
• Verlust 17 Mio. $
  
• Cash 129 Mio. $
  
• MK 49 Mio. $
  

- support operations through the third quarter of 2024

https://investors.iobiotech.com/news-events/news/...ults/default.aspx

Zahlen für Q2/23

• keine Umsätze
  
• Verlust 21 Mio. $
  
• Cash 110 Mio. $
  
• MK 107 Mio. $
  

- $75 million private placement

- expected to support operations into the fourth quarter of 2025

https://iobiotech.com/press-releases/...8-fe15-4ae2-aa0d-a198f9cf8d8e

Zahlen für Q3/23

• keine Umsätze 
  
• Verlust 22 Mio. $
  
• Cash 166 Mio. $
• MK 62 Mio. $

https://investors.iobiotech.com/news-events/news/...ults/default.aspx

Zahlen für Q1/24

• keine Umsätze
  
• Verlust 19 Mio. $
  
• Cash 118 Mio. $
  
• MK 91 Mio. $
  

- Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with pembrolizumab still expected in Q3 2024; outcome of primary endpoint of progression free survival (PFS) is now projected to occur in first half of 2025

- expected cash runway into the fourth quarter of 2025

https://investors.iobiotech.com/news-events/news/...ghts/default.aspx

• Die Studie, die IO102-IO103 plus Keytruda im Vergleich zu Keytruda allein testete, zeigte in der Zwischenzeit keine statistisch signifikante Verbesserung der Gesamtansprechrate, sagte das Unternehmen am Freitag und werde daher im nächsten Jahr unverändert bis zur vollständigen Analyse fortfahren

https://www.oncologypipeline.com/apexonco/...im-miss-slows-io-biotech

Zahlen für Q2/24

• keine Umsätze
  
• Verlust 21 Mio. $
  
• Cash 101 Mio. $
  
• MK 63 Mio. $
  

- Phase 3 interim analysis outcome still expected in Q3 2024 for the overall response rate (ORR) in the pivotal trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with Merck’s anti-PD-1 therapy KEYTRUDA^® (pembrolizumab) in patients with advanced melanoma; outcome of primary endpoint of progression free survival (PFS) expected in first half of 2025

- Cash position is expected to support operations into the fourth quarter of 2025

https://investors.iobiotech.com/news-events/news/...ghts/default.aspx